ClinicalTrials.gg
CompletedNCT03754309Updated Jan 27, 2023

A Study of KY1005 in Patients With Moderate to Severe Atopic Dermatitis

A Phase 2 interventional study of KY1005 and Placebo in Dermatitis, Atopic, sponsored by Kymab Limited. Completed at 19 sites in 4 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-01-27.

Sponsored by Kymab Limited (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
89
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies testing amlitelimab in Dermatitis, Atopic — none open to participants now, 4 under way, 3 of them phase 3. amlitelimab · Dermatitis, Atopic.

Enrollment
10th of 11
89 · median 589
Started
2018
the only one that year
Phase 2
4 of 11
none open now
Registered
1st of 11
by date
Lead sponsor
2 of 11
Kymab Limited

Among the 11 studies testing amlitelimab in Dermatitis, Atopic, this one is the 10th largest by enrollment, is the only one that started in 2018, is one of 4 in phase 2, and was the 1st registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

None of the 11 studies testing amlitelimab in Dermatitis, Atopic is open now. The open studies under Dermatitis, Atopic, anywhere →

About amlitelimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies testing amlitelimab in Dermatitis, Atopic as a file.
02

Study summary

The purpose of this research study is to investigate if KY1005 results in improvement of eczema when given to participants with moderate to severe disease. Side effects of KY1005 will also be explored.

Read the detailed description

Phase 2a, randomized, double-blinded, placebo-controlled study to evaluate the efficacy, safety and tolerability of two doses of KY1005 in adults with moderate to severe atopic dermatitis whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.

03

Conditions studied

  • Dermatitis, Atopic

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (greater than or equal to [>=] 18 years but less than [\<] 75 years of age) with Atopic Dermatitis (AD) for 1 year or longer at Baseline (Day 1; prior to first administration of Medicinal Product [IMP]).
  • Eczema Area and Severity Index (EASI) of 12 or higher at the Screening Visit and 16 or higher at Baseline.
  • validated Investigator Global Assessment (vIGA) of 3 or 4 at Baseline.
  • AD involvement of 10 percent or more of body surface area at Baseline.
  • Documented history, within 6 months prior to Baseline, of either inadequate response to topical treatments or inadvisability of topical treatments.
  • Must have applied a stable dose of topical bland emollient (simple moisturizer, no additives [e.g., urea]) at least twice daily for at least 7 consecutive days before Baseline.
  • Able and willing to comply with requested study visits/telephone visits and procedures.
  • Able and willing to provide punch of both lesional and non-lesional skin at Baseline.
  • Able and willing to provide written .

Exclusion criteria

Exclusion Criteria:

  • Recent treatment within specific time windows before the baseline visit for the management of atopic dermatitis such as topical or systemic , biologic or therapies and/or phototherapy.
  • Known history of or suspected significant current , including history of invasive opportunistic infections despite infection resolution or otherwise recurrent infections of abnormal frequency or prolonged duration.
  • Basal and squamous cell skin cancer in the last 3 years prior to Baseline. Any other in the last 5 years prior to Baseline (excluding in situ cervical carcinoma).
  • Severe concomitant illness that would in the Investigator's opinion inhibit the participant's participation in the study, including for example, but not limited to, renal disease, neurological conditions, heart failure and pulmonary disease.
  • Laboratory values at the Screening Visit:
  • a. Serum creatinine > 1.6 milligrams per deciliter (mg/dL) (141 micromole per liter [mcmol/L]) in female participants and > 1.9 mg/dL (168 mcmol/L) in male participants;
  • b. (ALT) or aspartate aminotransferase (AST) > 1.5 × (ULN);
  • c. count \< 100*10\^9/L;
  • d. (Hb): Male \< 13.5 g/dL and Female \<12 g/dL;
  • e. White blood cell count (WBCC) \< 3.0*10\^9/L;
  • f. \< 2.0*10\^9/L;
  • g. Absolute lymphocyte count \< 0.5*10\^9/L;
  • h. Total > ULN.
  • Participation in any other clinical study, including non-interventional studies.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
89 participants (actual)

Study arms

  • Experimental
    KY1005 lower dose

    Low dose KY1005

    Drug: KY1005

  • Experimental
    KY1005 higher dose

    High dose KY1005

    Drug: KY1005

  • Placebo comparator
    Placebo

    Matched placebo

    Drug: Placebo

Interventions

  • DrugKY1005

    A human anti-OX40 ligand monoclonal antibody

    Also known as: SAR445229

  • DrugPlacebo

    Matched placebo

06

What researchers measure

Primary outcomes

  1. Percentage change in Eczema Area and Severity Index (EASI)

    Time frame: Baseline to day 113

  2. Incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Baseline to day 113

Secondary outcomes

  1. Percentage and absolute change from Baseline in EASI over time

    Time frame: Baseline to day 113

  2. Change in epidermal thickness

    Time frame: Baseline to day 113

  3. Change in keratin 16 staining of skin biopsies

    Time frame: Baseline to day 113

  4. Percentage of patients with at least a 50% reduction in EASI (EASI 50)

    Time frame: Baseline to day 113

  5. Percentage of patients with at least a 75% reduction in EASI (EASI 75)

    Time frame: Baseline to day 113

  6. Percentage of patients with at least a 90% reduction in EASI (EASI 90)

    Time frame: Baseline to day 113

  7. Change in Validated Investigator Global Assessment (vIGA)

    Time frame: Baseline to day 113

  8. Percentage of patients with a response of vIGA 0 or 1

    Time frame: Baseline to day 113

  9. Change in SCORing of Atopic Dermatis (SCORAD) Index

    Time frame: Baseline to day 113

  10. Change in affected body surface area (BSA)

    Time frame: Baseline to day 113

  11. Change in Patient Orientated Eczema Measure (POEM)

    Time frame: Baseline to Day 113

  12. Change in Patient Orientated SCORing of Atopic Dermatitis (PO-SCORAD) Index

    Time frame: Baseline to day 113

  13. Change in Dermatology Quality of Life Index (DLQI)

    Time frame: Baseline to Day 113

  14. Change in Numerical Rating Scale (NRS) for pruritus

    Time frame: Baseline to day 113

07

Study locations

19 sites
  • Kymab investigational site 106
    Kiel, Germany
  • Kymab investigational site 113
    Leipzig, Germany
  • Kymab investigational site 207
    Gdansk, Poland
  • Kymab investigational site 216
    Katowice, Poland
  • Kymab investigational site 206
    Krakow, Poland
  • Kymab investigational site 212
    Kraków, Poland
  • Kymab investigational site 213
    Kraków, Poland
  • Kymab investigational site 214
    Kraków, Poland
  • Kymab investigational site 203
    Olsztyn, Poland
  • Kymab investigational site 210
    Poznań, Poland
  • Kymab investigator site 201
    Rzeszow, Poland
  • Kymab investigational site 204
    Warsaw, Poland
  • Kymab investigational site 202
    Wroclaw, Poland
  • Kymab investigational site 304
    Córdoba, Spain
  • Kymab investigational site 303
    Madrid, Spain
  • Kymab investigational site 302
    Seville, Spain
  • Kymab investigational site 315
    Valencia, Spain
  • Kymab investigational site 420
    Harrogate, United Kingdom
  • Kymab investigational site 402
    Sheffield, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2020, 16 months.

Of 195 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.

Counting every sponsor, half of 223 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 19, 2018
First posted
Nov 27, 2018
StartActual
Dec 13, 2018
Primary completionActual
May 12, 2020
CompletionActual
Oct 8, 2020
Last update
Jan 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03754309
Lead sponsor
Kymab Limited
Responsible party
Sponsor
First posted
Nov 27, 2018
Start date
Dec 13, 2018
Primary completion
May 12, 2020
Completion
Oct 8, 2020
Last update
Jan 27, 2023

Study contacts

Stephan Weidinger, MaHM
principal investigator · University Hospital Schleswig-Holstein, 24105 Kiel, Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amlitelimab

Start the discussion